多西他赛同步放化疗治疗老年II/III期食管癌的2期试验
这项多中心2期研究评估多西他赛同步放化疗在≥70岁II/III期(非T4)食管癌患者中的疗效与毒性,计划入组37例但因入组缓慢提前终止,实际入组16例。2年生存率62.5%,中位生存期27.7个月,完全缓解率43.8%,≥3级急性食管炎发生率31.3%。
要点
- ≥70岁II/III期非T4食管癌患者接受多西他赛每周10 mg/m2共6周同步60 Gy/30次放疗。
- 16例中14例(87.5%)完成放化疗,2年生存率62.5%,中位生存期27.7个月。
- ≥3级急性毒性以食管炎(31.3%)最常见,需进一步降低食管炎发生率。
核心结论
- 多西他赛同步放化疗可能成为老年II/III期食管癌的治疗选择,尤其适合不适合手术或含顺铂治疗的患者。
- 该方案仍需改进以降低食管炎的发生率。
研究设计与样本
- 多中心2期研究,计划入组37例,实际入组16例后因入组缓慢提前终止。
- 入组患者为≥70岁、临床II/III期(非T4)食管癌,接受多西他赛每周10 mg/m2共6周同步放疗60 Gy/30次。
- 主要终点为2年生存率。
主要发现
- 16例患者中14例(87.5%)完成放化疗。
- 2年生存率为62.5%(90% CI,42.5-82.5)。
- 中位生存期为27.7个月(95% CI,23.3-32.2个月),中位无进展生存期为15.2个月(95% CI,5.4-25.0个月)。
- 7例达到完全缓解,完全缓解率为43.8%(95% CI,19.8-70.1)。
- ≥3级急性毒性包括食管炎(31.3%)、厌食(12.5%)、白细胞减少(6.3%)、中性粒细胞减少(6.3%)、血小板减少(6.3%)、黏膜炎(6.3%)和感染(6.3%)。
关键数值与推荐
- 多西他赛剂量为每周10 mg/m2,连续6周。
- 放疗剂量为60 Gy分30次。
- ≥3级晚期毒性包括食管炎(12.5%)、胸腔积液(12.5%)、肺炎(6.3%)和心包积液(6.3%)。
临床怎么用
- 对于≥70岁、不适合手术或含顺铂治疗的II/III期(非T4)食管癌患者,可考虑多西他赛同步放化疗。
- 治疗期间需密切监测并管理食管炎等毒性。
局限性
- 研究因入组缓慢提前终止,实际样本量仅16例,低于计划的37例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The most effective treatments in elderly patients with esophageal cancer remain a subject of debate. This multicenter phase 2 study was designed to evaluate the efficacy and toxicity of chemoradiation therapy (CRT) with docetaxel (DTX) in elderly patients with stage II/III (non-T4) esophageal cancer. METHODS AND MATERIALS: Patients ≥70 years of age with clinical stage II/III esophageal cancer received DTX at a weekly dose of 10 mg/m2 during 6 consecutive weeks and concurrent radiation therapy (60 Gy in 30 fractions). The primary endpoint was the 2-year survival rate, and the required number of enrolled patients was 37. RESULTS: Between July 2008 and January 2011, 16 patients were enrolled. The study was prematurely closed because of slow accrual. Characteristics of the patients were as follows: median age, 77 years (range, 73-81); performance status 0/1, 4/12; and clinical stage IIA/IIB/III, 3/4/9. Of the 16 patients, 14 (87.5%) completed the CRT. The 2-year survival rate was 62.5% (90% confidence interval [CI], 42.5-82.5). The median survival time was 27.7 months (95% CI, 23.3-32.2 months) and the median progression-free survival was 15.2 months (95% CI, 5.4-25.0 months). Seven patients achieved complete response, resulting in a complete response rate of 43.8% (95% CI, 19.8-70.1). Grade 3 or higher acute toxicities included esophagitis (31.3%), anorexia (12.5%), leukopenia (6.3%), neutropenia (6.3%), thrombocytopenia (6.3%), mucositis (6.3%), and infection (6.3%). Grade 3 or higher late toxicities included esophagitis (12.5%), pleural effusion (12.5%), pneumonitis (6.3%), and pericardial effusion (6.3%). CONCLUSIONS: CRT with DTX might be a treatment option for elderly patients with stage II/III esophageal cancer, particularly for patients who are medically unfit for surgery or cisplatin-containing therapy. However, further improvements of this therapy are required to decrease the incidence of esophagitis.
引用
- Ohba A, Kato K, Ito Y, et al. Chemoradiation therapy with docetaxel in elderly patients with stage II/III esophageal cancer: A phase 2 trial. Adv Radiat Oncol. 2016. PMID: 28740892. doi:10.1016/j.adro.2016.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。